Satellos Bioscience Inc. has received orphan drug designation and rare pediatric disease designation from the FDA for SAT-3153 for the potential treatment of Duchenne muscular dystrophy (DMD). The first-in-class oral small-molecule therapeutic is designed to restore the innate muscle regeneration process independent of dystrophin and regardless of exon mutation status.
Ichnos Sciences Inc.’s first-in-class T-cell engaging trispecific antibody, ISB-2001, has been granted orphan drug designation by the FDA for the treatment of multiple myeloma.
The FDA has awarded orphan drug designation to HL-001, a novel lysophosphatidic acid receptor-1 (LPA1) antagonist being developed for idiopathic pulmonary fibrosis (IPF) by Ube Corp. and Hilung Inc.
Dtx Pharma Inc.’s Dtx-1252, an investigational small interfering RNA (siRNA) therapeutic, has been awarded U.S. orphan drug designation for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A).
Vanda Pharmaceuticals Inc.'s antisense oligonucleotide (ASO) VCA-894A has been awarded orphan drug designation by the FDA for the treatment of Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S), caused by cryptic splice site variants within IGHMBP2.
Antengene Corp. Ltd.'s Claudin 18.2 antibody-drug conjugate (ADC) ATG-022 has been granted two orphan drug designations consecutively by the FDA for the treatment of gastric cancer and pancreatic cancer.
Ocugen Inc.’s OCU-410ST (AAV5-hRORA) has been awarded orphan drug designation by the FDA for the treatment of ABCA4-associated retinopathies, including Stargardt disease, retinitis pigmentosa 19 (RP19) and cone-rod dystrophy 3 (CORD3) diseases.
Researchers in Australia have developed new cancer cell line models for pediatric cancers with the lowest survival rates, with a focus on high-risk central nervous system tumors such as glioblastoma.
RSS
